VOL. 27 • NO. 2 • APRIL 2012



THE OFFICIAL NEWSLETTER OF THE WORLD FEDERATION OF NEUROLOGY

Plan Addresses Epilepsy in Latin America

BY JEFF EVANS Elsevier Global Medical News

ast year, member nations of the Pan American Health Organization endorsed a strategy and action plan on epilepsy that seeks to improve the identif ication, treatment, and human rights of people with epilepsy.

It is the first time that the Pan American Health Organization (PAHO) – the oldest regional health organization in the world – approved a neurological program as a priority, according to Dr. Marco T. Medina, who is the World Federation of Neurology's newly elected regional director for Latin America.

"This is one of the most important examples of what a region can do together for a neurological problem, because this is the f irst time regionally that a neurological problem has been put in the agenda of the go vernments as a priority," Dr. Medina said in an interview.

The impetus for the strategy and action plan derives from a number of earlier resolutions and programs from the W orld Health Or ganization (WHO) and the PAHO, including the 1997 Global Campaign Ag ainst Epilepsy, the 2000 Declar ation of Santiago on Epilepsy in Latin America, and

the WHO's 2008 Mental Health Gap Action Program, which recognized epilepsy as one of eight priority conditions.

The strategy and action plan is sorely needed. In the Americas, about 5 million people have epilepsy, but it is estimated that more than half of those with epilepsy in Latin America and the Caribbean



A patient receives an EEG evaluation for epilepsy as part of the first phase of the Honduras Treatment Gap Project in the city of Juticalpa.

The International League Against Epilepsy (ILAE) appointed Dr.

See Epilepsy • page 8

INSIDE

Australia

The training and career patterns of three neurologists from 19th-century Australia illustrate different patterns of interchange between the neurologies of Europe and Australia. PAGE 4

Tanzania

The WFN Association of Parkinsonism and Related Disorders collaborated with the Medical Association of Tanzania to hold a Parkinson's and **Movement** Disorders conference. PAGE 7

Argentina

Chagas-Mazza disease is beginning to emigrate from endemic areas in Latin America to developed countries. PAGE 8

have no access to services, according to the WHO.

Medina; Dr. Jorge Rodriguez, chief of PAHO Mental Health; and

Knowledge of New Mutation in ALS, Dementia Grows

BY BECKY McCALL Elsevier Global Medical News

n recent months, the discovery of the C9ORF72 mutation has added fresh insight into the causes of frontotemporal dementia and amyotrophic lateral sclerosis, and no w a series of new studies describes the fr equency of the mutation and ho w the mutation reveals itself clinically

in a spectrum of phenotypes in patients with either disease.

The series of studies found that the mutation most often is associated with behavioral variant frontotempor al dementia (FTD), and occurred in 2%-5% of patients with spor adic FTD and 15%-48% of patients with familial FTD. For amyotrophic lateral sclerosis (ALS) patients, the mutation occur red in 4%-

7% of sporadic cases and 22%-43% of familial cases. Another 20%-40% of patients who show symptoms of both diseases had the mutation; the rate reached almost 50% among these patients with a f amily history of ALS or FTD. Some studies r eported finding the mutation in 0%-28% of patients who present with the pro gressive nonfluent aphasia variant of FTD.

The eventual clinical impact of identifying the C9ORF72 mutation is the availability of a population of at-risk carriers of the mutation to aid r esearch into the preclinical phase of disease, said Dr. Kevin Talbot, professor of motor neuron biology at the University of Oxford, England. "Rather than work in the phase of established disease, w hich may be intr actable to diseasemodifying therapy, this provides a new depar ture to 'f ill in' a phase in the natur al history of ALS w hich has hither to not been amenab le to study ." Dr. Talbot w as a coauthor on a study that scr eened 4,448 patients with ALS and 1,425 patients with FTD f or the m utation (Lancet Neurol. 2012 March

See Mutation • page 14

In This Issue of World Neurology

The WFN Nominating Committee is now accepting nominations for an elected trustee post. See Page 2

The Latin American Federation of Neurological Societies was recently formed. See Page 3

EDITOR IN CHIEF'S COLUMN



New Leadership to Continue WFN Mission ith this issue, I end my 4-year term as editor in chief of World Neurology. It has been both fun and educational to take a very broad view

MARK HALLETT, MD

of the activities of our profession.

Generally, neurological problems are the same around the w orld, except for the increased incidence of various infections in Africa, India, and v arious parts of South America. The infections have been highlighted because e very neurologist needs to know about them; with incr eased mobility an y inf ection

might show up anywhere.

However, there is also epilepsy, stroke, and neurodegenerative disease. Here we need to educate doctors and health care workers to bring modern medicine to patients everywhere. An inter esting trend that will help in this r egard is telemedicine. The WFN is our prof essional organization and it builds links between the world's neurologists. It can help tack le the world's problems, but it needs the help of everyone.

WORLD NEUROLOGY, this ne wsletter, can play a role in bring ing news of all these concerns and the Federation's activities to e very neurolo gist. In my tenure, the siz e and scope of WORLD NEUROLOGY increased to report on more information about the WFN and provide more neurolo gy ne ws. T he f eedback that I have received is that this effort has been successful.

However, two factors are at pla y to change the format yet again. One is that the cur rent f ormat is e xpensive, and, two, is that electronic media are getting more popular and widel y a vailable. Looking forward, W ORLD NEUROLOGY may well become all electronic.

There ar e man y per sons to thank. Renée Matthews was my managing editor from the Inter national Medical Ne ws Group (IMNG) most of the time. She was assisted by Jeff Evans, who now will take over the operation. They have been great. The editorial board has been helpful, particularly Ale x T selis, the liaison to the Journal of Neurological Sciences, who contributes articles to the newsletter, and Michael Finkel, who is always full of good ideas and has lots of contacts around the world. T he officers of the WFN – Dr . Vladimir Hachinski, Dr. Raad Shakir, and our e xecutive dir ector, K eith Ne wton have been supportive and helpful.

Past President, Dr. Johan Aarli, hired me for this job and was very helpful as I began. He is no w taking over the position of editor in chief of WORLD NEU-ROLOGY going forward. I cannot think of a better choice, and I wish him good times. Most important, I have to thank all those neurologists around the world who have contributed articles. It is the newsletter of all the world's neurologists and Johan Aarli will be counting on your continuing help.

Nominating Committee Recommendations for the 2012 Election

he nominating committee of the World Federation of Neurology has r ecommended the following candidates for the elected tr ustee post that will become vacant on Sept. 9, 2012, at the Annual General Meeting of the Council of Delegates: ▶ Prof. Wolfgang Grisold (Aus-

tria)

► Dr. Raul Federico Pelli-Noble (Argentina)

▶ Prof. Jean Schoenen (Belgium)

Anyone can make additional nominations by obtaining the supporting signatures of five or more authorized delegates and submitting the name(s) of the individual(s) in question to the Secretary-Treasurer General, in care of the London Secretariat office.

The nominations need to arrive at least 30 days prior to the date of the Council of Delegates meeting.



Visit the World Federation of Neurology's newly redesigned Web site at www.wfneurology.org. You can download current and past issues of World Neurology.



WORLD FEDERATION OF NEUROLOG Editor in Chief Dr. Mark Hallett (USA)

EDITORIAL ADVISORY BOARD

Dr. Pierre Bill (South Africa); Dr. William M. Carroll (Australia); Dr. Jagjit S. Chopra (India); Dr. Michael Finkel (USA); Dr. Osvaldo Fustinoni (Argentina); Dr. Francesc Graus (Spain);

Dr. Alla Guekht (Russia); Dr. Steven Ringel (USA); Dr. Daniel Truong (USA); Dr. Alexandros Tselis (USA)

WFN OFFICERS

President: Dr. Vladimir Hachinski (Canada)

First Vice-President: Prof. Werner Hacke (Germany) Secretary-Treasurer General: Dr. Raad Shakir (United Kingdom)

ELECTED TRUSTEES

Dr. Wolfgang Grisold (Austria); Dr. Ryuji Kaji (Japan); Dr. Gustavo Roman (USA)

CO-OPTED TRUSTEES

Donna Bergen (USA); Stephen Sergay (USA)

REGIONAL DIRECTORS

Dr. Ahmed Khalifa (Pan Arab); Dr. Robert Griggs (North America); Prof. Richard Hughes (Europe); Dr. Alfred K. Njamnshi (Pan Africa); Dr. Ana Mercedes Robles de Hernandez (Latin America); Dr. Ching-Piao Tsai (Asia-Oceania)

EXECUTIVE DIRECTOR

Keith Newtor World Federation of Neurology Hill House, Heron Square Richmond, Surrey, TW9 1EP, UK Tel: +44 (0) 208 439 9556/9557 Fax: +44 (0) 208 439 9499 info@wfneurology.org

EDITOR OF THE JOURNAL OF THE NEUROLOGICAL SCIENCES Dr. Robert Lisak (USA)

WORLD EUROLO

World NEUROLOGY, an official publication of the W orld Federation of Neurology, provides reports from the leadership of the WFN, its member societies, neurologists around the globe, and news from the cutting edge of clinical neurology Content for WORLD NEUROLOGY is provided by the World Federation of Neurology and IMNG Medical Newswire.

Disclaimer: The ideas and opinions expressed in World NEUROLOGY do not necessarily reflect those of the World Federation of Neurology or the publisher. The World Federation of Neurology and Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Editorial Correspondence: Send editorial correspondence to WORLD NEUROLOGY, 5635 Fishers Lane, Suite 6000. Rockville, MD 20852, U.S.A.; worldneurology@elsevier.com; Phone +1-800-798-1822

Address Change: Fax change of address to +1-973-290-8245

POSTMASTER: Send change of address (with old mailing label) to World Neurology, Circulation, 60 B, Columbia Rd., 2nd Fl., Morristown, NJ USA 07960

WORLD NEUROLOGY, ISSN: 0899-9465, is published bimonthly by Elsevier Inc., 60 B, Columbia Rd., 2nd Fl., Morristown NJ 07960. Phone +1-973-290-8200: Fax: +1-973-290-8250.

©Copyright 2012, by the World Federation of Neurology



GLOBAL MEDICAL RESEARCH Publisher Peter F. Bakker

FISEVIER GLOBAL MEDICAL NEWS

A Division of IMNG Medical Media

President IMNG Medical Media Alan J. Imhoff

Editor in Chief Mary Jo M. Dales

Executive Editors Denise Fulton, Kathy Scarbeck

Managing Editor Jeff Evans

Audience Development Manager Barbara Cavallaro

Executive Director, Operations Jim Chicca

Director, Production and Manufacturing Yvonne Evans Struss

Production Manager Judi Sheffer

Creative Director Louise A. Koenig

EDITORIAL OFFICE

5635 Fishers Lane, Suite 6000 Rockville, MD 20852 +1-240-221-4500 Fax: +1-240-221-2541

INTERNATIONAL ADVERTISING

Chris Woods 32 Jamestown Road Camden London NW1 7BY +44 207424 4454 c.woods@elsevier.com

PRESIDENT'S COLUMN



VI ADIMIR HACHINSKI, MD

ican F ederation of Neurological Societies w as

he de velopment of a Latin Amerlaunched during

the 13th Pan American Congress of Neurology in La Paz, Bolivia, held March 4-8. This follows the Mar rakesh Proclamation for the f ormation of such a Federation during the World Congress of Neurology in Marrakesh, Morocco, Nov. 12-17, 2011. T his was initiated by Gustavo Roman and Ana Robles, the outgoing Regional Director for Latin America, and representatives from the Latin American countries: Juan Carlos Dur an (Bolivia), Francisco Cardoso (Brazil), Sergio Castillo (Chile), Jesus Rodriguez (Colombia), Dennis Chinchilla (Costa Rica), Ana M. Robles (Dominican Republic), Oscar Del Brutto (Ecuador), Marco Tulio Medina (Honduras), Ricardo Rangel Guerra (Mexico), F ernando Gr acia (P anama), Alejandro Scar amelli (Ur uguay), and Santiago Fontiveros (Venezuela).

The World Federation of Neurology (WFN) of fered to consider pro viding through its grants program resources to create an infrastructure for the new Federation until such a time as a mor e permanent sour ce of income can be obtained. In par t to suppor t the ne w Federation, and in part because having more frequent Congresses of Neurolo-

gy will foster neurology in mor e r egions, the dele gates decided to mo ve the P an American Cong resses from a 4-year cycle to a 2-year cycle in par t-

nership with the WFN, the host society, and the newly formed Pan American Federation of Neurological Societies. T he delegates of Brazil, Mexico, Panama, Paraguay, Puerto Rico , and Venezuela ha ve e xpressed inter est in hosting the Pan American Congress of Neurology. F or pr actical reasons, moving from a 4- to a 2-y ear c ycle will not be feasible until after the ne xt P an

American Congress of Neurology to be held in 2016.

In line with a new democratic spirit within the WFN , it w as decided that the new Regional Director would not be a ppointed, b ut be elected. Carlos Ketzoian (Uruguay) suggested a list of desirable attributes of such an individual, a description complemented b y further suggestions by the dele gates. Candidates were invited to participate



The Formation of the Latin American Federation

Of Neurological Societies

Puerta del Sol (The Sun's Gate) is symbolic of the highly sophisticated culture that thrived in the area of Bolivia and surrounding countries between 700 and 1200 AD.

in the election, provided that they were nominated by a minimum of two delegates from par ticipating countries. Two candidates emerged, Marco Tulio Medina from Honduras and Ricardo Allegri from Argentina. Both were invited to pr esent their vision to the delegates, followed by questions. After each had an opportunity of stating his proposals and ans wering the questions of the dele gates, a secr et vote was held

and Mar co T ulio Medina was v oted the ne w R egional Dir ector f or Latin America. Ricar do Alle gri will serve as a V ice President of the WFN Applied Research Committee.

The main task of the new Regional Director is to develop a str ucture f or the new Federation in preparation of the democratic election of Officers in 2 y ears. He will be aided b y the Commission headed by Ana Robles that will de velop a constitution and bylaws, and by the P an American Congress of Neurology Congress Committee that will include Juan Carlos Duran, organizer of the 13th Pan American Congress.

The leaders of WFN activities in the Americas will

be Gustavo Roman. Chair of the Latin America Initiati ve; Ricar do Nitrini (Brazil), Vice Chair; and Mar co Tulio Medina, ex officio Vice President as Regional Director. Their duties will include coordinating educational pro grams in Latin America in collaboration with the WFN.

May the sun shine upon the ne wly formed Latin American F ederation of Neurological Societies!

MEETING REPORT

Bringing Neurology to Pan American Primary Care

BY SILVIA KOCHEN, MD

The n umber of neurologists in Bo-livia is much lower than the rate per capita r ecommended b y the W orld Health Organization, and so it is essential to provide the basic tools for the diagnosis and tr eatment of neurological disorders to primary care physicians and family doctors.

For that reason, a conference was held during the 13th Pan American Congress of Neurology in La Paz, Bolivia, March 4-8, 2012. It featured focused training on basic concepts of methodology and epidemiology and on the most fr equent neurological diseases such as stroke, epilepsy, dementia, headache, and central nervous system infections. The conference was sponsored by the World Federation of Neurology, the Pan American Society of Neuroepidemiology, and the International League Against Epilepsy's Latin American Commission.

The conference was or ganized as a

classroom cour se with fr ee b ut compulsory registration and a total of 20 hours of teaching, divided into 4 hours per day. In ag reement with the health authorities of Bolivia, each authorized participant w ho had complete atten-

TRAINING FOCUSED ON BASIC CONCEPTS OF METHODOLOGY AND EPIDEMIOLOGY AND THE **MOST FREQUENT NEUROLOGICAL DISEASES.**

dance in the course received a legal certificate to place in their tr aining curriculum. Each participant also received a CD with all the materials presented in each class.

A total of 350 people enrolled for the course, but admission had to be declined to about 100 a pplicants because of a

lack of space in the physical location of the event. The students' daily presence and their interest and active participation in the seminars were remarkable.

In the last hour of the final day of the course, we asked all participants to give their thoughts about the conf erence anonymously. There was a very positive outlook, and the initiati ve was highly valued among the attendees. They said that they had never before been asked to participate in a similar acti vity. T hey emphasized the impor tance of the information received and noted the lack of taboos with many of the concepts seen during the course to eliminate the fear of seeing patients with neurological diseases. They identified not only the difficulty in diagnosis but also in monitoring these patients . T hey were highly likely to implement w hat the y had learned into their dail y practice. They emphasized the importance of diagnostic and tr eatment protocols, as well as the educational value of reviewing "clinical cases." Some criticiz ed the lack of teaching materials bef ore the conf erence and r equested the r epetition of similar activities.

We consider ed this cour se to be a valuable e xperience. It demonstr ated that it is essential to consider the importance of providing knowledge about the car e of neurological disor ders to primary car e physicians in de veloping countries. We suggest repeating this experience in other countries, and attracting an audience of general practitioners by inviting leading neurology specialists in each congress of neurology.

DR. KOCHEN is the epilepsy section head in the division of neurology at Hospital "R. Mejía," a researcher at CONICET (National Council for Scientific and Technical Research), a professor of neurology at the University of Buenos Aires, and the Education Secretary of the Latin American Commission of the International League Against Epilepsy.

FROM THE WFN HISTORY GROUP

Over the Seas: Three 19th-Century Australia Neurologists

BY MERVYN J. EADIE, AO, MD, PHD

uring the f inal two decades of the $19^{\,\rm th}$ century three Australian men, bor n within a decade of one another, undertook the long sea voyage from Sydney to Britain to f urther their medical and neurological experience. Their subsequent careers followed rather different courses that manifest different patterns of interchange between the neurologies of Europe and the antipodes. They were pioneers of a career pattern that many Australian neurologists and neuroscientists followed during the 20th century while Australian neurology matured and increasingly became educationally self-sufficient.

The first-generation Australians George Edward Rennie (1861-1923), Alfr ed Walter Campbell (1868-1937),



and Gr afton Elliot Smith (1871-1937) were all educat-

ed in Ne w South W ales to the stage of university entry. Rennie, who was born in Sydney, took a B A de gree from the University of Sydney because no A ustralian university medical cour se was available at the time and then sailed to London in 1883. He graduated with an MB in 1887 and with an MD a year later. After returning to Sydney, he worked as a

physician and patholo gist. In 1898, he ag ain sailed to London, acquiring further neurological knowledge at Queen Square and qualification as a member of the Royal College of Physicians. Returning to Sydney, he achieved a considerable local reputation as a physician with major neurolo gical inter ests, pub lishing some neurological case r eports and r eview-type ar ticles. However, his career had little international neurological impact.

Campbell was born on a pastoral property near present-day Canberra. Although he was young enough to enter the new Sydney University medical cour se, he sailed to Britain in 1886 and g raduated MB ChM (Edinburgh) in 1889. He spent 2 y ears gaining experience at Queen Square, in various British mental asylums, in Prague, and in Vienna with Baron Richard von Krafft-Ebing. His thesis, "The pathology of alcoholic insanity," brought him an Edinburgh MD.

pathologist to the Rainhill Asylum in Liverpool, England. In that time, he pub lished a substantial n umber of major neuropathological studies. These included his collaboration with Henry Head on the f amous investigation of the pathology of herpes zoster that defined the distribution of the der matomes and his g reat monograph of 1905, "Histological Studies of the Localisation of Cerebral Function," which provided the first detailed account of the cytoarchitectonics of the primate and human cerebral cortex.

Campbell later returned to Australia after an absence of nearly 20 years. He spent the r emainder of his life in Sydney practicing clinical neurology. Others had preempted him for appointments in neuropathology and psychological medicine. Campbell pub lished further neuropathological and neurohistolo gical studies of originality and merit, b ut his car eer in Australia, distinguished enough though it was, did not fulfil his earlier outstanding promise. He had been a way from his homeland for too long before returning.

Smith was born in the provincial town of Grafton. He undertook the Sydney medical course and then spent several years carrying out neuroanatomical studies in that University's anatomy department, gaining an MD.

With a scholarship, he sailed from Sydney to Britain, subsequently doing further research in the Cambridge anatomy department before occupying, successively, chairs of anatomy at Cairo, Egypt; Manchester, England; and University College, London. During his career, he was responsible for a great deal of anthropological, neuroanatomical, and paleopatholo gical research, and collaborated with Dr. William H.R. Rivers in work on psychological trauma.

Smith also was involved in the Piltdown man affair. He was one of several authorities who accepted that a skull and ja whone found in 1912 in a g ravel pit in East Sussex, England, were fossil remains of a hitherto unrecognized human ancestor; 40 years later they were proved to be part of a deliberate hoax. Nonetheless, Smith proved to be a very considerable figure in

the Egyptology, anthropology, and neuroanatomy of his time, a fellow of the Royal Society, and a knight. On two occasions, in 1914 and 1924, he returned to A ustralia for visits, but never again lived in his homeland.

Most Australian neurologists in at least the first two-thirds of the 20th century tended to f ollow training

Benign Essential

Blepharospasm

RESEARCH FOUNDATION


INCORPORATED



George Edward Rennie

and career patterns resembling that of Rennie. A few resembled Smith's, and e ven fewer, Campbell's. Few attained such g reat international scientific distinction as Campbell or Smith.

DR. EADIE is emeritus professor of clinical neurology and neuropharmacology at the University of Queensland and honorary consultant neurologist at the Royal Brisbane and Women's Hospital, both in Brisbane, Australia.



For 13 y ears, Campbell w as medical of ficer and

REQUEST FOR RESEARCH GRANT PROPOSALS

- Funds up to US \$150,000 are available annually for support of research into new treatments, pathophysiology, and the genetics of benign essential blepharospasm and Meige syndrome (cranial and oromandibular dystonia). Research into photophobia, dry eye, and apraxia of eyelid opening as they relate to benign essential blepharospasm and Meige syndrome and their treatment will also be considered for funding.
- M.D. or Ph.D. required for principal investigator.
- Non-U.S. citizens working at institutions abroad are also eligible to apply for a research grant.
- Deadline to apply is Aug. 31.

Grant guidelines and a listing of previous grants may be obtained from: Benign Essential Blepharospasm Research Foundation, Inc. P.O. Box 12468, Beaumont, TX 77726-2468 • Ph: 409-832-0788 Fax: 409-832-0890 • E-mail: bebrf@blepharospasm.org • Web: www.blepharospasm.org



ELSEVIER *presents*

...titles from our NEUROLOGY portfolio





For more information please visit: www.journals.elsevierhealth.com

Working Group Is Interconnecting Young Neurologists Worldwide

BY WALTER STRUHAL, MD

epresentatives from many regions within the World Federation of Neurology have become member s of the International Working Group of Young Neurolo gists and Trainees since its f ormation in 2009 and its inaugur al meeting at the World Congress of Neurology in Bangkok, T hailand. The IWGYNT's vision is to advocate for the interests of young neurologists on a worldwide basis within the World Federation of Neurology (WFN). W e ar e proud that we have one member elected to r epresent our group within the WFN' s Education Committee.

Our mission is to:

► Represent the inter ests and initiatives of residents and y oung

neurologists with a single voice.Establish netw orking among

young neurologists.Support international training ex-

change. The group is organized as a panel

consisting of two dele gates from each continent. Dele gates may be sent only by a national or inter national neurological body r epresenting young neurologists in that area. Currently Africa, Asia, Europe, and Australia and New Zealand have sent delegates to the IW GYNT. In the first 2 y ears of our e xistence, w e have focused on estab lishing a network among young neurologists in the continents we are representing.

Africa

Our two dele gates from the P an African Association of Neurological Sciences, Dr. R ufus Ak inyemi and Dr. F austin Y epnjio, acti vely promoted the IW GYNT in man y African meetings. They established a database of young African neurologists and inter connected them, which led to a tr emendous improvement of organization within young African neurologists.



IWGYNT neurologists Walter Struhal, Xenia Kobeleva, Johann Sellner attend WCN 2011.

Asia

Our delegate from the Association of South East Asian Nations Neurological Association, Dr . Sur at T anprawate, was extremely active in promoting the IW GYNT at Asian meetings and administr ating the Facebook page of the IWGYNT. He has established a working network of young Asian neurologists.

We are very proud to support the establishment of a young neurologists and trainees group in New Delhi, conceptualized by Prof. Man Mohan Mehndir atta. W e o we Prof. Mehndiratta many thanks for his dedication to young neurologists' issues.

In 2011, Dr. Tissa Wijeratne, originating from Sri Lanka and working in Australia, has joined as second Asian delegate. His ad vocacy ef fort f or young neurolo gists has r ecently r esulted in the initiation of the Asia Pacific Association of Young Neurologists and Trainees (www.apaynet.org). These ef forts mer ged with ef forts from Dr . T anprawate and Prof. Mehndiratta, and w e ar e conf ident that this will be a strong r epresentation ad vocating y oung neurolo gists for the Asia and the Pacific region.



The Young Neurologist Workshop in Marrakesh, chaired by Dr. Stephen M. Sergay and Dr. Wolfgang Grisold, featured lively discussion.

Australia/New Zealand

The IWGYNT's delegates from the Australian and New Zealand Association of Neurologists (ANZAN), Dr. Kate Ahmad and Dr. Jason Burton, already have a working network of young neurologists via ANZAN. They are currently trying to foster training exchange with other continents

Europe

The delegates of the European Association of Young Neurologists and T rainees (EA YNT, www.eaynt.org), Dr . Cristian Falup-Pecurariu and myself, are enjoying a w ell-working young neurologists network in Europe. We promoted the IW GYNT at many European meetings and several online and print ar ticles and tried to acti vely inter connect all groups involved.

North America

There are cur rently no r epresentatives from Nor th America, b ut w e are in close cooper ation with the American Academy of Neurology's Consortium of Neurology Residents and F ellows (CNRF). Member s of the IWGYNT are for the second time invited to contribute to the CNRF's meetings at the AAN congress.

Central America

Dr. Cumara O'Carroll, a committed young neurologist at the Mayo Clinic in Scottsdale, Ariz., USA, is a liaison to the IWGYNT. She is interested in supporting young neurologists in Centr al America, and to gether with Dr. Mar co T. Medina, she r ecently initiated an exchange program with Honduras.

South America

Unfortunately, the IWGYNT has currently cooper ations with onl y individual South American y oung neurologists.

WCN 2011

At the 2011 World Congress of Neurology in Marrakesh, Morocco, Prof. Wolfgang Grisold and Prof. Mostafa El Alaoui Faris generously offered a free workshop and a fr ee booth at the congress. The IWGYNT, together with the g reat support of the EAYNT, organized a free workshop and a booth. Both initiati ves were successful and well visited.

DR. STRUHAL is chair of the International Working Group of Young Neurologists and Trainees and a past president of the European Association of Young Neurologists and Trainees. He works in the Department of Neurology and Psychiatry at the General Hospital of the City of Linz (Austria).

Calendar of International Events

2012

7th World Congress for NeuroRehabilitation May 16-19, 2012 Melbourne, Australia www.dcconferences.com.au/wcnr2012/Home

SSIF Annual Meeting in Multiple Sclerosis

May 18-19, 2012 Valencia, Spain www.seronosymposia.org

12th International Conference on Myasthenia Gravis and Related Disorders May 21-23, 2012 New York, USA www.nyas.org/MG12

Third International Conference "Advances in Clinical Neuroimmunology" ACN 2012 May 31-June 1, 2012 Vienna, Austria

www.acn2012.eu

13th Asian Oceanian Congress of Neurology June 4-8, 2012 Melbourne, Australia www.aocn2012.com

47th Annual Congress Canadian

Neurological Sciences Federation June 6-8, 2012 Ottawa, Ontario www.cnsfederation.org/congress.html

22nd Meeting of the European Neurological Society

June 9-12, 2012 Prague, Czech Republic www.congrex.ch/ens2012

1st African Epilepsy Congress

June 21-23, 2012 Nairobi, Kenya www.epilepsynairobi2012.org

16th Congress of the European Federation of Neurological Societies Sept. 8-11, 2012 Stockholm, Sweden www.efns.org/efns2012

10th European Congress on Epileptology (ECE)

Sept. 30 – Oct. 4, 2012 London, United Kingdom www.epilepsylondon2012.org

8th World Stroke Congress (WSC 2012) Oct. 10-13, 2012 Brasilia, Brazil www2.kenes.com/stroke/Pages/Home.aspx

2013

XXI World Congress of Neurology Sept. 21-26, 2013 Vienna, Austria www2.kenes.com/wcn/Pages/Home.aspx

REGIONAL FOCUS: LATIN AMERICA

Addressing the Need for Reliable Data in Emerging Countries

The World Health Organization has stated that it is crucial that countries all o ver the w orld impro ve their data collection systems to assess health indicators and measur e the impact of

public health policies and resource utilization at the population le vel. T his is particularly important for noncommunicable diseases (NCDs) such as cerebrovascular disease in Latin American countries where relevant epidemiological data ar e scar cely available.

During a United Nations meeting Sept. 19-20, 2011, participants from 113 member states, including 34 heads of state and 2 r epresentatives from the American Heart Association and the World Stroke Organization, analyzed the prob lem of NCDs, par ticularly in emer ging countries. The main goal w as to gener ate strategies for improvement through coordinated research initiatives and a glob-



al monitoring framework, mainly in lowand middle-income countries, where 80% of deaths from stroke and coronar y disease occur each year. There was general agreement as to the World Health Orga-

BY LUCIANO SPOSATO, MD, MBA

Dr. Sposato is director of the stroke center at the Institute of Neurosciences, Favaloro Foundation University Hospital, and chairman of the department of neurology at IN-ECO (Institute of Cognitive Neurology), both in Buenos Aires.

nization's (WHO's) coordinating role.

As part of the initiative on improving data collection systems and improving the measurement of public health policies, the WHO has identified three major challenges regarding NCDs:

► The capacity of countries to respond (for example, by improving inadequately funded or nonoper ational health infrastructure in many countries, expanding health system capacity and giving a higher priority to NCDs, and developing national NCD programs and policies on stroke).

Advancing toward multisector action

BY OSVALDO FUSTINONI, MD

Dr. Fustinoni is professor of neurology at the Buenos Aires University Medical School and chief of cerebrovascular diseases at the Instituto de Neurociencias Buenos Aires, Argentina.

(for example, by systematically engaging the health sector with others across government).

► Monitoring trends and measuring results (for example, through high-quality and adequately supported NCD surveillance of risk f actors, outcomes, and health-system r esponses, with a common set of indicators).

In regard to the third challenge, consis-

tent information of the actual and precise picture of NCDs in most Latin American countries is desperately needed.

Latin American health systems could certainly benef it by improving the v ol-

ume and quality of research on NCDs. Population-based studies from Latin America ar e necessary to provide local reliable data and should be specif ically designed to r epresent most populations with low-middle and upper-middle income economies . The inadequate extrapolation of facts from European or Nor th American sources, that surely do

not represent the Latin American reality, should be a voided. It is pointless to attempt secondary stroke prevention policies solely on the basis of those sources, without knowing the cause of the initial strokes in the f irst place. T he de velopment of entirely Latin American studies would be the m uch needed steppingstone to gener ate proper pub lic health policies in the region.

MEETING ROUND-UP

Movement Disorders Course in Tanzania a Success

BY KAREN P. FREI, MD

The World Federation of Neurology Association for Parkinsonism and R elated Disor ders collabor ated with the Medical Association of Tanzania to hold a Parkinson's and Movement Disorders conference at the Protea Hotel Courtyard, Dar es Salaam, on Feb. 11.

The meeting was well attended with approximately 30 physicians from all o ver the countr y. The meeting happened to occur f ollowing the end of a physician's strike in Tanzania. Dr. Namala Mkopi, the current president of the Tanzanian Medical Society, helped to organize this meeting along with Dr. Tanya Simuni and Dr. Daniel Truong from the United States.

Dr. Sim uni of Northwestern Uni versity, Chicago, spoke on the differential diagnosis of Parkinson's disease and on the nonmotor symptoms of Parkinson's. I gave a talk about P arkinson's disease and the tr eatment of Parkinson's disease. In between talks, Dr. Ryan Uitti of the Mayo Clinic, Jacksonville, Fla., USA, demonstrated the proper neurological exam. He also presented information on park insonism, dementia, and tr emors. Dr. Hubert Fernandez of the Cleveland Clinic in Cleveland, Ohio, USA, presented on the topics of multiple system atrophy, pro gressive supr anuclear palsy, and chor ea. Dr. Truong of the Parkinson's and Movement Disorders Institute, Orange County, Calif., USA, spoke on dystonia and other mo vement disorders, including r estless legs syndrome and myoclonus. Some presentations also focused on nonmedication-based tr eatments such as cueing therapy - walking in time to a metronome beat to improve gait in Parkinson's disease.

Infectious diseases such as HIV/AIDS comprise the majority of health issues in T anzania, b ut with advancement in available treatments for infectious disease, and as the population ages, there will be greater numbers of people with chronic conditions such as Parkinson's disease. But resources in Tanzania are limited. The



Faculty and some of the participants of the workshop in Dar es Salaam, T anzania, on Feb. 11, 2012. In the front row are Dr. Ryan Utti (Mayo Clinic, Jacksonville, Fla., USA), Dr. Karen P. Frei (Parkinson's and Movement Disorder Institute, Orange County, Calif., USA), Dr. Tanya Simuni (Northwestern University, Chicago, USA), Dr. Namala Mkopi from the Tanzania Medical Association, Dr. Huber Fernandez (Cleveland Clinic, Ohio, USA) and Dr. Daniel Truong (Parkinson's and Movement Disorder Institute, Orange County, Calif., USA).

entire country has only three neurologists and one MRI scanner. Man y patients contin ue to use tr aditional healers or home remedies to help with their symptoms

Currently, the pr evalence of Parkinson's disease in sub-Saharan Africa is controversial. Data on this subject are limited, b ut the f ew studies that ha ve been conducted reported prevalences lower than in other parts of the world.

A recent study estimated the pr evalence of Parkinson's disease in Tanzania to be 20 per 100,000 population, which is still lower than the prevalence reported in the United Kingdom. Patients with Parkinson's disease in Tanzania are usually not diagnosed or tr eated for the disease, which has been r egarded to be a par t of the normal aging process by many in the country. In Tanzania, standard medications used to treat Parkinson's disease are difficult to obtain and expensive. Most

patients are unable to afford medication to treat their diseases and the y will ration the medications provided by the government. For example, in part of one sociology study in rural Tanzania, 28 patients with Parkinson's disease were identified, the majority of which were not previously diagnosed. Only two were taking medication to treat the symptoms of the disease.

DR. FREI is director of clinical research at the Parkinson's and Movement Disorders Institute, Orange County, Calif., USA.

Chagas-Mazza Disease and Stroke: A Call for Attention

Emigration of infected patients to developed countries has changed the epidemiology of the disease.

fter malaria and schistosomiasis, Chagas disease is the thir d most common par asitic inf ection worldwide, af fecting mostl y South American populations w ho ha ve lo w incomes and restricted access to medical care. It is caused by the flagellate protozoan Trypanosoma cruzi. The Brazilian physician Carlos Chag as described the

disorder in 1909. In Argentina, it is known as Chagas-Mazza disease, in honor of Salvador Mazza, the Argentine ph ysician w ho in 1926 investigat-



ed and described its epidemiolo gic cycle and over the years became one of its leading researchers worldwide.

About 14 million people ha ve emigrated to Europe, Nor th America, Japan, and Australia in the past 20 years, many of them asymptomatic infected patients coming from endemic regions. This resettlement, together with that of thousands of others who moved from rural to urban areas in South America, has changed the epidemiolo gy of the disorder, which has consequently become an emerging epidemiologic prob-



lem in de veloped countries. It is believed that Charles Darwin himself may have caught the disease during his voyage to South America in the early 19th century.

The major complications – disab ling cardiomyopathy and stroke - occur in the chronic phase. Cer ebral infarctions have been described in autopsy series , case-

BY MARÍA CRISTINA

Dr. Zurrú is a neurologist in the cerebrovascular disease section at the Hospital Italiano de Buenos Aires, Argentina.

control studies. clinical r eports, and cohort studies. Chagasic cardiomyopathy is independently associated with ischemic stroke Chronic hear t

disease causes

heart f ailure, several types of arrhythmias, sudden car-

diac death, and systemic thromboembolism. The main risk f actors associated with ischemic stroke include car diac apical aneur ysm, atrial f ibrillation, m ural thrombus, and left v entricular dysf unction. Stroke occurs more often in women and younger patients. In contrast, hypertension, diabetes mellitus, dyslipidemia, and smoking are less common in stroke patients with chag asic car diomyopathy. Other causes of stroke encounter ed in these patients , such as carotid

atherothrombosis and small vessel occlu-

sion, ar e probab ly associated with the presence of coexistent atherosclerotic vascular risk and not with chronic arterial inflammation due to

parasitic infection. Educational campaigns ar e needed to reduce the high infection risk in South America. **BE IMMUNOLOGICALLY SCREENED** Currently, around 100 million people live in the endemic

regions where Triatoma infestans (the household insect responsible for T. cruzi transmission) is de-

tected. Appro ximately 25% ha ve the chronic form of the condition and are at risk of heart failure and subsequent ischemic stroke.

Early diagnosis and secondar y pr evention measur es should be encouraged in chag asic stroke. Around 20%-25% of infected stroke patients ar e classified as cryptogenic. Consequently, patients with ischemic car dioembolic or cr yptogenic stroke should be immunologically screened for T. cruzi infection, especially if they come from endemic regions.

Clinical trials are needed to assess the efficacy of anticoagulant ther apy for primary and secondar y stroke pr evention in this condition. Although some studies have reported an association between chronic T. cruzi infection and cognitive impair ment with or without ischemic stroke, the r elation betw een

ischemic stroke and dementia has not been properly investigated. The World Health Organization control measur es

initiated against T. infestans have had a dramatic ef fect in lowering the prevalence of the disorder. Ho wever, the long latency period before the chronic clinical stage arises will maintain this illness as an impor-

tant public health problem for decades. Therefore, prior to the indication of any therapy or pr evention strategy, the inclusion of Chagas-Mazza disease in the differential diagnosis of stroke is essential.

References

PATIENTS WITH ISCHEMIC

CARDIOEMBOLIC OR

CRYPTOGENIC STROKE SHOULD

FOR T. CRUZI INFECTION.

Carod-Artal FJ, et al. Stroke in asymptomatic Trypanosoma cruzi-infected patients. Cerebrovasc. Dis. 2011;31:24-8.

Jesus PA, et al. Stroke history and Chagas disease are independent predictors of silent cerebral microembolism in patients with congestive heart failure. Cerebrovasc. Dis. 2011;31:19-23

Lima-Costa MF, et al. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambui cohort study of aging. Stroke 2010;41:2477-82.

Machado FS, et al. Chagas heart disease: report on recent developments. Cardiol. Rev. 2012:20:53-65.

36/100,000 in 2005 and pr evalence declined from 15/1,000 in 1997 to 12/1,000 in 2005, b ut these were not significant differences. However, the rate of symp-

tomatic epilepsy caused by neurocysticercosis declined

munity interventions included an education and media

campaign, animal husbandry training for pig farmers,

construction of water projects and proper sewage dis-

clinic, deworming of Salamá County school students,

In 1997, the tr eatment gap for epilepsy in Salamá

County was 58%, based on the pr evalence of active

posal, construction of a mater nal and child health

and ongoing taeniasis sur

2011;52:1177-85).

significantly from 37% in 1997 to 14% in 2005. Com-

New Projects Are Underway in Countries

Epilepsy • from page 1

Dr. Carlos Acevedo, secretary general of the International Bureau for Epilepsy, to propose the strategy and action plan. They worked with a team of more than 30 experts from Latin America to draft the document, which received final approval at a P AHO meeting in Washington, D.C., USA, on Sept. 29, 2011. P AHO member states agreed to:

► Make epilepsy a national health polic y priority b y implementing programs that are adapted to conditions in each country.

► Strengthen le gal fr ameworks to protect the human rights of people with epilepsy and ef fectively enforce relevant laws. ► Strengthen primary care sys-

tems and integrated services networks to promote universal and equitable access to medical car e for people with epilepsy.

▶ Ensure the availability of the four antiepileptic drugs that are considered essential for treatment: phenobarbital, phenytoin, carbamazepine, and valproic acid.

▶ Improve neurological services to detect and manage cases at the primary care level.

► Support effective participation by the community, patient associations, and family members in activities designed to improve the care of people with epilepsy.

▶ Promote educational initiatives within and between countries to combat stigma and discrimination against people with epilepsy.

▶ Provide the means to improve the production, assessment, and use of information in the field of epilepsy.

▶ Strengthen partnerships between the health sector and other sectors and promote collaboration between nongovernmental organizations, academic institutions, and key social actors.

The document is meant to outline a fr amework for "each country to develop its own agenda specific to its

The document is meant to outline a framework for 'each country to develop its own agenda specific to its needs.'

DR. MEDINA

needs," said Dr. Medina, dean of the School of Medical Sciences at the National A utonomous University of Honduras, Tegucigalpa, and thir d vice pr esident of the ILAE. He noted that the task force will meet again in November 2012 at the Latin American Congress of Epilepsy in Quito,

THE HONDURAS TREATMENT **GAP PROJECT IS AN EXAMPLE OF A NATIONAL PROGRAM THAT COULD BE APPLIED IN OTHER COUNTRIES.**

epilepsy. More recently, a cross-sectional study involving house-to-house scr eening of 2,000 r andomly selected households in the nearby city of Juticalpa found a prevalence of active epilepsy of 6.5/1,000 individuals and a treatment gap of 48% for active epilepsy, according to Dr. Medina and his associates. Several other efforts are already underway in other Latin American countries that address the PAHO strategy and action plan, Dr . Medina said. In northern Peru, the Bill and Melin-

da Gates Foundation has provided funding to de velop programs to r educe the incidence of preventable epilepsy. In Colombia, new le gislation is being introduced that is designed to protect people with epilepsy. Brazil has a

veillance (Epilepsia

demonstrative program supported by the WHO that aims to improve education and r educe the treatment gap for people with epilepsy. Programs in Chile have been successf ul in impro ving access to antiepileptic drugs for people with epilepsy.



Ecuador, to evaluate the strategy and action plan. The Honduras Treatment Gap Project is one e xample of a national pro gram that Dr . Medina hopes can be a pplied in other countries to improve community

involvement in the care of people with epilepsy and to incr ease the number of people w ho r eceive treatment or prevention services.

The first phase of the demonstration project sought to deter-

mine the treatment gap and prevalence of epilepsy in Honduras. In a study of the impact of community interventions on the incidence of epilepsy and the prevalence of active epilepsy in r ural Salamá County, incidence declined from 93/100,000 individuals in 1997 to

Save The Date



5th Congress of the Pan Asian Committee for **Treatment and Research in Multiple Sclerosis (Pactrims)** Thursday 13 to Saturday 15 September 2012, Beijing, China

You are cordially invited to participate in the 5th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis in Beijing, China. Healthcare professionals from 18 countries are expected to congregate at this meeting to learn, discuss and share opinions, ideas and best practices on Multiple Sclerosis.

As a participant, you will:

- Be better equipped to treat your patients, based on new and practical knowledge to improve your patient care. A fully customizable scientific program to meet your individual educational needs.
- Keep abreast on the latest therapeutic, technological and practice management tools.
- Connect and network with the MS community to share experiences, best practices, and get advice that will benefit you in your practice throughout the year

For more information on PACTRIMS 2012 please visit :

Program Highlights Dancing as Therapy for Parkinson's

BY MARK HALLETT, MD Editor in Chief, WORLD NEUROLOGY

Dancing is r eceiving new attention f or its ther apeutic value in Parkinson's disease in a netw ork of new dance classes that have spread inter nationally. One of the most well-known and successful modern dance companies in the United States the Mark Morris Dance Group (MMDG) is promoting a program called Dance for PD that it developed with the Brooklyn (N.Y., USA) Parkinson Group.

The Dance for PD project at MMDG be gan in 2001 when Olie Westheimer, the director of the Brook lyn Parkinson Group, conceived the idea based on her ex-



Misty Owens leads members of the Brooklyn Parkinson Group at the Mark Morris Dance Center.

periences in both studying dance and seeing patients. Olie is the wife of neurologist and Parkinson's disease specialist, Dr. Ivan Bodis-Wollner. She approached MMDG, and the pro gram was initiated with support of the dance group itself and some foundation grants.

Dance combines physical exercise, mental function, rhythmic stimulation, and a good time. Because it is usually done in a group setting, it also encourages social interaction and friendships. It is likely that patients would more likely continue to participate in it than in a simple e xercise such as treadmill running (unless perhaps they can simultaneously listen to music or watch television). The caregiver also benefits from dance.

There is already published evidence that tango provides benefits to patients. In one study, there was a head-to-head comparison betw een tango and American ballroom dancing, and tango seemed slightly better, although both were good.

A developing body of data shows that dance has value for gait, balance, fatigue, quality of life, and enjoyment. It also is w ell established that physical activity is good for a person's health and longevity, and that both physical and mental activity are good for maintaining co gnitive f unction. Physical and

mental activity are valuable for the average healthy person, and a ppear to be doub ly valuable in patients with Parkinson's disease. Physical activity works in man y ways, including the production of an important neurotrophic factor, called brain-derived neurotrophic factor.

The dance classes at MMDG are firmly based on the fundamental principles of instruction that inform all forms of dance; these principles apply not only to the physical act of dancing, but they also place considerable emphasis on cognitive aspects such as rhythm, sequencing, cr eativity, and aesthetics. The teaching of choreography in classes brings all these aspects of dance into focus.

The Dance for PD program has spread internationally, and now has more than 1,500 students in 60 locations in the USA, Europe, and India who participate in



COURTESY DR. MARK HALLETT

David Leventhal (left), the program manager and an active teacher for Dance for PD, meets with the director of the Brooklyn Parkinson Group, Olie W estheimer, and her husband, Dr. Ivan Bodis-Wollner, a neurologist and Parkinson's disease specialist.

classes based on the original Brooklyn model.

The program also trains teachers in the methods and approaches that seem most successful. The Dance for PD network is rapidly expanding, and the program will shortly have a series of videos available to introduce the fundamental method to patients who can't attend a class or for patients who want to practice between classes.

Parkinson's disease, like most diseases, should not be treated with medications alone. Lif estyle and activity are also impor tant. Dopaminer gic medications and maybe also deep br ain stimulation are helpful, but so too is dance. Why not get better and ha ve fun at the same time?

More information about Dance for PD is available at danceforparkinsons.org.

WFN ASIA INITIATIVE

n his 2010

inauguration

speech, W orld

Neurology Pres-

ident Vladimir

Hachinski con-

veyed a clear

Federation of



RYUJI KAJI, MD

message: " Asia has more than 60% of the global population, yet in some ar eas, the education of neurology to y oung neurolo-

gists does not keep up with the patients' needs of neurological car e. For this reason, it is essential for WFN to help vitalize the educational activity in this region among others."

Since I w as appointed as the head of the Asia Initiative, I have been trying to promote the educational activities in neurology with the aid of many friends inside and outside Asia. It is for this reason that I invite you to attend the Asian-Oceanian Congress of Neurology (AOCN) 2012 meeting in Melbour ne, Australia, June 4-8.

'Let's Share a Dream'

Prof. Matthew Kier nan of Australia, the A OCN pro gram chair, and Prof. Ching Piao Tsai of Taiwan, the President of the Asian-Oceanian Association of Neurology (AOAN), are trying their best to plan an attractive program with speakers from all o ver the world for AOCN and other educational cour ses, and to find as many sponsors as possible to improve the financial status of the meeting. Prof. Tsai and his colleagues have decided to hold the A OCN every 2 y ears instead of every 4 years, and if the congress is a success, future meetings could attract more and mor e people o ver the y ears, and might be held e very y ear. A successful meeting will mean that Asian

and Oceanian societies ar e now getting closer to becoming a unified neurology organization.

I have talked with Prof. T sai and his colleagues, and it is clear that w e share a dream of having an annual meeting in the future that is compar able with the European F ederation of Neurological Societies cong ress in Europe, or the American Academy of Neurology meeting in North America.

We met last No vember at the W orld Congress of Neurology in Mar rakesh, Morocco, and had an Asia Initiati ve meeting. A total of 17 people from inside and outside the r egion attended the meeting and had man y productive discussions. We reached three major points to pursue in our future activities:

▶ First, it is important for associations to hold meetings in collaboration with one another. It is str ategically important to use e xisting fr ameworks, including A OCN. W e could ask the ASEAN (Association of Southeast Asian Nations) Neurolo gical Association, which is headed by Prof C.T. Tan of Indonesia, and the East Asian Neurology Forum (an inf ormal get-to gether of those from K orea, T aiwan, China, Hong Kong, and Japan) to synchronize meetings, so that a large attendance can be e xpected. J oint meetings betw een any of these two organizations are now being planned f or the 2014 A OCN meeting in Hong Kong.

► Second, it is essential to w ork with other inter national or ganizations, such as the Movement Disorder Society or the International Federation of Clinical Neurophysiology. Both of these or ganizations have agreed to have a satellite basic movement disorder course or a basic EMG hands-on cour se at the A OCN 2012 meeting.

► Third, we will ask g roups of young neurologists to join these activities through the Internet. This promising idea was proposed by Dr. Tissa W ijeratne of Australia, who also represents Sri Lankan neurologists. He is now forming the Asia P acific Association of Young Neurologists and Trainees.

We need y our help f or this dr eam, which also embodies that of WFN itself. Please come and join A OCN 2012 for a wide variety of educational opportunities at a r easonable cost f or tr avel, accommodation, and registration. The new iPad app for Clinical Neurology News is now available!





To download the app and the latest editions, search for Clinical Neurology News in the iTunes store.

Each edition contains:

- dynamic and unique content from the print issue of Clinical Neurology News
- multimedia coverage of the latest meetings in neurology and perspective on key developments in clinical studies, practice, and policy
 - links to references and web pages of sources within articles

 ability to share articles via e-mail or social media

Surgical Removal Boosts Brain Thrombus Recovery

BY MITCHEL L. ZOLER Elsevier Global Medical News

NEW ORLEANS – An in vestigative, minimally invasive surgery for reducing intracranial clot volume following an intracerebral hemorrhage showed promise in results from a randomized trial.

In the controlled study , 54 patients who underw ent clot r emoval b y mini-



Minimally invasive clot removal improved outcomes, Dr. Daniel F. Hanley said.

mally invasive surgery (MIS) had a 10% increased rate of achieving a modif ied Rankin Scale (mRS) score of 1-3 at 180 days, compared with 39 patients managed by conventional, medical ther apy, Dr. Daniel F. Hanley said at the International Stroke Conference.

"These data ma y establish a sur gical goal for MIS of reducing clot burden to 15 mL or less b y 3-4 da ys" after the intracerebral hemorrhage (ICH), said Dr. Hanley, a prof essor of neurology and neurosurgery at Johns Hopkins University in Baltimore, Md., USA. The study enrolled patients within a da y of their ICH with a clot v olume of at least 20 mL; the a verage volume for the 93 patients was 40 mL.

The next step will be a pi votal, controlled study planned to enroll 500 patients at 35-50 centers, with an expected study dur ation of 5 years. Dr. Hanle y and his associates ar e seek ing f unding from the U .S. National Institutes of Health.

The study used a combination of intracerebrally infused recombinant tissue plasminogen activator (rTPA) and placement of a cannula into a patient's skull to remove thrombolysed clot, a method that "has been around" for several years, but never before underwent assessment as a standar dized procedur e and in a prospective, controlled study, Dr. Hanley said in an interview.

The study enrolled patients at 35 international sites w ho were 18-75 y ears old and had a spontaneous, supratentorial ICH with a stable clot. They also had received rTPA within 54 hour s of their first diagnostic CT e xamination. T he mean age of the enrolled patients was 61 years, two-thirds were men, and the patients randomized to MIS received their initial rTPA treatment an average of 48 hours after the ICH began. During an initial phase of the study patients received 0.3 mg of rTPA, b ut during the later phase the dose increased to 1.0 mg, the amount that most of the MIS patients received.

Safety data showed that patients treated with MIS had a 7-da y mortality rate of 2 and a 30-da y mor tality of 15%, compared with a r ate of 8% at 30 da ys in the medically treated control patients. Symptomatic bleeds occurred in two of the MIS patients and one of the controls, and a brain infection occurred in none of the MIS patients and in one control patient. During follow-up out to 180 days, mortality rates were virtually identical, about 20%, in both ar ms of the study, and dropouts also reached similar levels in both arms, about 45%.

During their first 4 days in the study, MIS patients had an average 65% reduction in their intr acerebral clot v olume, compared with no change in the control patients. The two-thirds reduction with MIS corresponded to an average 28 mL drop in volume.

The study's primar y outcome w as mRS at 180 days, with data available for 50 MIS patients and 33 controls. No patients in either group had an mRS of 0. An mRS of 1 occurred in two MIS patients and none of the controls. An mRS of 1-3 occurred in about 35% of the MIS patients and about 25% of the controls.

The prespecified goal of MIS was removal of at least 15 mL of clot, and surgeons achie ved this in about a thir d of the MIS patients. When patients attained that level of clot reduction, they had a statistically significant, 3.7-fold increased rate of having an mRS of 1-3 at 180 days, compared with patients w ho did not reach this goal.

Among the subgroup with a clot burden of at least 50 mL, MIS led to a 17% increased rate of patients achieving an mRS of 1-3, compared with the controls, Dr. Hanley said. Among patients treated medically, those with a clot burden on entry of about 20 mL often had an mRS of 1-3 at 180 da ys, but among those who began with a clot of at least 30 mL, only three patients r eached an mRS of 1-3.

The minimall y in vasive sur gery tested in this study is probab ly the most promising a pproach developed for treating the devastating disease of intracerebral

hemorrhage.

TARY

The results showed a 10% increase in the rate of patients recovering to a modified Rankin Scale score of 1-3; it is a pr etty signif icant r esult. It results in less disability for patients and less burden to their families.

The most important predictor of outcome was the size of the clot; if you can do anything meaningful to reduce the siz e, it should benef it patients. But agg ressiveness in r emoving clot m ust be balanced against minimizing manipulation of brain tissue. The goal is to r emove as m uch clot as possib le without doing damage. The results did not include information on brain edema following surgery, but it look s like despite the trauma of intervention

> patients on balance had better outcomes.

This was a phase II study, so the results now need to be replicated in additional patients. At this point, it remains ethical to randomize patients to r eceive either this tr eatment or con ventional therapy. This is a very important treatment to f urther ex-

DR. STEVEN R. LEVINE is professor of neurology and emergency medicine at the State University of New York Downstate Medical Center, Brooklyn, N.Y., USA. He said that he had no disclosures. Dr. Levine made these comments in an interview.

amine.

Need for CT Perfusion Imaging in Acute Stroke Questioned

BY MITCHEL L. ZOLER Elsevier Global Medical News

NEW ORLEANS – The extra time needed for CT perfusion imag ing in patients with an acute ischemic stroke may not be warranted, based on a retrospective analysis of 418 patients tr eated at nine U .S. ter tiary stroke centers.

The analysis showed that the outcomes in patients assessed using CT perfusion (CTP) were very similar to those in patients w orked up with noncontr ast CT (NCCT), and that CTP added an average of 48 minutes to the time ela psed between the start of imaging and the completion of the reperfusion procedure, Dr. Rishi Gupta said at the International Stroke Conference.

"Additional imag ing did not tr anslate into better clinical outcomes or reduced hemorrhage rates, raising the question of whether NCCT is good enough," said Dr. Gupta, a neurolo gist at Emor y University and director of the acute stroke network at Grady Health System, both in Atlanta, Ga., USA.

Because the analysis was retrospective, the next step is a prospective, randomized study to compare the impact of NCCT and CTP, Dr. Gupta noted. Despite this limitation, he said he and his associates at Grady Health are convinced by the findings and have already scaled back their use of CTP to rely more on NCCT.

"We cut back quite a lot on our CTP based on these findings," although a majority of centers that perform endovascular perfusion on acute stroke patients "tolerate the delay and get CTP," he said in an interview. "We need to do a randomized study" to settle the question, he added.

The data set compiled from the nine par ticipating U.S. centers included 418 eligible patients who underwent imaging prior to endo vascular reperfusion therapy between September 2009 and December 2011. Of these, 227 (54%) had CTP and 191 (46%) had NCCT.

The study included consecuti ve patients with an occlusion of the middle cerebral or internal carotid artery treated within 8 hours of symptom onset. The analysis excluded patients with a posterior circulation stroke, those who underwent MRI, and those with a thrombus in their anterior cerebral or distal middle cerebral artery. The patients' average age was 67 y ears, and their a verage National Institutes of Health Stroke Scale score was 18.


The analysis showed successful reperfusion in 65% of the NCCT patients and in 71% of those imaged with CTP. A good clinical outcome – a modifed Rankin Scale score of 0-2 at 90 days after hospitalization – was achieved in 37% of the NCCT and 38% of the CTP patients. Mortality was 23% in the NCCT and 21% in the CTP patients. The rates of symptomatic and asymptomatic hemorrhage were also similar in the two subgroups. None of these between-group differences were statistically significant. In a multivariate analysis, the use of CTP was not a significant determinant of a good clinical outcome.

Average time from the start of CT imaging to reperfusion was 175 minutes in the NCCT patients and 223 minutes in the CTP group.

Dr. Gupta presented two additional analyses designed to compare outcomes using the two imaging methods in closely matched subgroups. In one analysis, he focused exclusively on the 291 patients in the database who had occlusions at the M1 site of the middle cerebral artery. In these patients, NCCT saved an average of 40 minutes, compared with CTP, and outcomes w ere not signif icantly better with CTP. In the second analysis, he categorized patients by their Alberta Stroke Program Early CT Score (ASPECTS). In the subgroup of 198 patients with an ASPECTS of more than 7 on a scale of 10, with 10 being nor mal, CTP did not lead to signif icant improvement in outcomes and took an average of 45 minutes longer to reperfusion, compared with NCCT.

Dr. Gupta has been a consultant to Concentric Medical, CoAxia, Rapid Medical, and Codman.

Leading resources in clinical neurology!



Journal of the Neurological Sciences

Official Journal of the World Federation of Neurology

Editor- in-Chief Robert P. Lisak, Department of Neurology, Wayne State University School of Medicine

The *Journal of the Neurological Sciences* provides a medium for the prompt publication of studies on the interface between clinical neurology and the basic sciences.

www.jns-journal.com

Parkinsonism and Related Disorders


Official Journal of the World Federation of Neurology Association of Parkinsonism and Related Disorders


Editors- in-Chief **R. F. Pfeiffer**, *University of Tennessee HSC*

Z.K. Wszolek, Dept. of Neurology, Mayo Clinic

Parkinsonism & Related Disorders publishes the results of basic and clinical research contributing to the understanding, diagnosis and treatment of all neurodegenerative syndromes in which Parkinsonism, Essential Tremor or related movement disorders may be a feature.

www.prd-journal.com





OBITUARY

Richard Koch Olney (1947-2012)

BY MICHAEL J. AMINOFF, MD, DSC

ichard Koch Olney died peacefully on Jan. 27 from amyotrophic lateral sclerosis, a disorder on which he had focused his energy as a physician, educator, and clinical investigator for many years before he himself was diagnosed with it.

He was born in Munich, Ger many, in 1947, where his father was an engineer in the U.S. Army. After a y ear in Ger many, several years in West Virginia and other parts of the United States, and a y ear in Japan, the f amily finally settled in Ok lahoma. He did his undergraduate studies at the University of Pennsylvania, Philadelphia, USA, and the Uni versity of Oklahoma, Norman, USA, following which he went to Baylor University, Houston, Tex., USA, where he received his MD degree in 1973. He then began residency training in psychiatry at the University of California, Los Angeles, USA, but soon transferred to the neurolo gy pro gram at the Or egon Health Sciences Uni versity (OHSU) in Portland, USA, becoming a board-certified neurologist in 1980. After a brief stint in practice, he joined the f aculty of OHSU before moving to the Uni versity of California at San Francisco (UCSF), where he became an associate professor in 1989 and a full professor in 1995.

He was appointed Associate Editor of Muscle & Ner ve in 1998, and to the editorial boar d of several other jour nals shortly thereafter. He held a n umber of offices in the various professional organi-



Through numerous articles and radio and TV appearances, Dr. Richard Koch Olney's personal battle with ALS gave the disorder a human face and dimension.

zations to which he belonged. He was the author of numerous original papers, review articles, and book chapters relating to his research interests, which initially focused on the use of electrophysiological techniques to investigate the operation of the neuromuscular system in health and disease and, mor e r ecently, on amy otrophic lateral sclerosis (ALS). Indeed, he personally created and directed the Comprehensive ALS Center at UCSF, and it is a cause for sadness that he himself eventually became a patient there, being cared for with devotion by the very staff whom

he had tr ained. His unit became one of the most respected units in the country. He had not mer ely knowledge but the wisdom to kno w ho w best to use that knowledge. That is a rare skill among clinicians and is w hat distinguishes the outstanding physician from the mediocre.

He worked long hours, many being devoted to patient car e. He always seemed to be calling patients with advice, support, and encouragement, and his compassion and kindness helped ease their distress and fears. He also had the rare ability to inspire others, his trainees, by his own example.

let others know what they did not know without upsetting or hurting them. He befriended many of his students and ne ver sought their thanks for the quiet help that he gave them. He had a f irst-class mind and the temperament of a gentleman. He also deliberately and courageously

He was a great clinical teacher who could

publicized his illness with the hope of increasing a wareness of the disease, becoming a national spokesperson on ALS. His efforts were rewarded by the Lifetime Achievement Award of the American Association of Neuromuscular & Electrodiagnostic Medicine, and by an award for public education from the American Academy of Neurology Foundation. The sad irony of his personal plight captured the attention of the media and, in the numerous articles that appeared about him in the national press and on radio and television programs, he discussed the nature of the disease, the impor tance of basic and clinical studies, and the need for controlled clinical trials of potential therapies. He thereby gave ALS a human f ace and dimension, coming to per sonify the disease to the gener al public and national agencies, both in the United States and overseas. This may yet prove to have been his g reatest achie vement, for it will undoubtedly help both individuals trying to cope with the disease and those concerned with advancing its treatment.

DR. AMINOFF is director of the Parkinson's Disease and Movement Disorders Clinic at the UCSF Medical Center.

Clinical Presentation Varies

Mutation • from page 1

9 [doi:10.1016/S1474-4422(12)70043-1]).

The discovery of the mutation and the subsequent characterization among patients who have FTD, ALS, both FTD and ALS, or primary progressive aphasia are just the f irst steps of many before treatments can be based on the ne knowledge, said Dr. Paul Schulz of the department of neurology at the University of Texas, Houston, USA, where his lab examines the mechanisms underl ying nor mal cognition and neurode generative disorders.

To illustrate his point, Dr. Schulz cited how the genes f or myotonic dystrophy and Huntington's disease were discovered in 1992 and 1994, r espectively, but r esearchers still kno w little about them. "We don't know what the y do, how the mutations cause problems, and how to replace them."

Preliminary findings underpinning the discovery of C9ORF72 w ere made in 2006 when investigators discovered that either FTD and ALS or a combination of both diseases were linked to a region on chromosome 9p21 in members of some families with the diseases. The big step came in September 2011 w hen two research groups independently identified the precise nature of the long-sought-after m utation (Neuron 2011;72:245-56; 257-68). It pro ved to be a GGGGCC hexanucleotide repeat in the noncoding region of the C9ORF72 gene.

Originally, no mutation had been f ound e ven after r epeated sequencing of the investigational r egion on chromosome 9p21, b ut eventually, the two

tern of inheritance and noticed that only the good gene appeared to be inherited rather than one gene from each par ent.

"After various experiments, it was realized that the abnor mal gene was invisible to gene sequencing because the hexanucleotide bound to itself," r elated Dr. Schulz. "As a r esult, it w as impenetrable by normal PCR [polymerase chain reaction] amplification. Now that this mechanism of mutation is known, I'm sure gene hunters are looking for **Mutation Screening in FTD and ALS** In the Lancet Neurolo gy study of 4,448

others that are also 'silent.' "

ALS patients and 1,425 FTD patients from the United States, Europe, and Australia, researchers found the C9ORF79 mutation in 7% of sporadic ALS in white patients and 4.1% of black patients. It was present in 6% of white patients with spor adic

FTD. T he r esults

of those with f a-

milial FTD or ALS

were more surpris-

ing, with the e x-

pansion present in

38% of all patients

with f amilial ALS

and 25% in w hite

patients with f a-

milial FTD.

The discovery and characterization of the mutation are the first steps of many before treatments can follow.

DR. SCHULZ

A series of four papers published in Brain by groups from the Netherlands; Manchester, England; London, England; and the Mayo Clinic in Rochester, Minn., and Jacksonville, Fla., USA, reported the results of screening large cohorts of patients with FTD totaling nearl y 1,200 cases. Overall, 7%-12% of the cohorts were found to have the mutation (Brain 2012;135:693-708; 723-35; 736-50; 765-83).

Another tw o pa pers and the same Mayo Clinic paper reported on the fr e-

quency of the mutation in patients with ALS. In 563 ALS patients from northern England, including 63 with a family history of ALS, the C9ORF72 e xpansion was found in 11%, but it occurred more often among patients with f amilial disease (43%) than with spor adic disease (7%) (Brain 2012;135:751-64).

Among patients with familial ALS, the mutation occurred in 38% of 141 Italian cases (including 57% in 21 Sardinian cases) and in 22% of 41 Ger man cases (Brain 2012;135:784-93).

Mayo Clinic researchers detected the mutation in 7% of 229 ALS patients and in 24% of 34 patients with familial ALS, parkinsonism, or dementia. Only 4% of sporadic ALS cases had the m utation. Among patients with a clinical phenotype of FTD and ALS, the prevalence of the mutation was 22%, but it approached 50% among those with a positi ve family history (Brain 2012;135:765-83).

"All of these statistics mean that this hexameric r epeat is f airly common amongst those with f amilial FTD or ALS, or especiall y FTD with ALS," according to Dr. Schulz. But familial FTD was present in only 40% of those with FTD, and f amilial ALS w as present in only 5% of ALS patients, he noted.

'This means that most sporadic FTD, Continued on following page

research g roups examined the pat-

BOOK REVIEW

History of Neurology Text Is a Welcome Addition

Eminent Neuroscientists: Their Lives and Works By K.B. Bhattacharyya

Kolkata, India: Academic Publishers and Association of Neuroscientists of Eastern India; 2011; 443 pp.

ost neuroscientists love history. Try to solicit any of the common search engines with the words "history of neurology" and y ou will f ind an amazing number of results, many more than for the history of other disciplines. This interest in history is a p-

parent not only in the number of books and ar ticles published on the subject, but also in the number of associations focused on the history of neurology. Those are to be found within each of the major professional groups, starting with the World Federation of Neurology, the American Academy of Neurology, the Amer-



ican Neurological Association, the International Brain Research Organization, and the European Federation of Neurological Societies; and ther e is of course the International Society for the History of the Neurosciences and its associated journal.

For his book, Dr. Kalyan B. Bhattacharyya has chosen to follow the per son-by-person approach, as did his illustrious pr edecessors Dr. Webb Ha ymaker¹ and Dr. Haymaker and Dr. Francis Schiller² – and also to some extent Stanley Finger, Ph.D.,³ although the latter embeds the history of the pioneers within an essay dealing with the science w orld around them. Like those abo ve authors, Dr. Bhattacharyya includes only European and U.S. personalities, with the lion's share devoted to those in the United Kingdom, Germany, and the United States.

French neurologists are also included, but to a lesser extent, since only three "modern age" neurologists (Théophile Alajouanine, Pierre Marie, and the Uzbekistan-born Konstantin Tretiakoff) are discussed. The author rightly acknowledges, albeit only in passing, the contribution of Jean Lhermitte, but he does not mention his son, F rançois Lher mitte. Other noticeab ly omitted French neurologists include Georges Guillain and Henri Gastaut, even though they all are "household names" among most neurologists.

Dr. Bhattachar yya provides a r eference dealing with neurologists from his own country (India), but perhaps a

BY FRANCOIS BOLLER. MD. PHD

Dr. Boller is a neurologist in Bethesda, Md., USA.

subsequent edition could include some prominent neurolo gists and

neuroscientists from other par ts of the world. With the exception of Sir Andrew Huxley, the author includes only per sons "w ho ar e no longer with us." It is a pleasant sur prise to find biographies of persons many of us may have known, such as Norman Geschwind, C. David Marsden, John Newsom-Davis, and Fred Plum.

This person-by-person approach to the history of neurology is complemented by books written in the mor e narrative format that was followed by Fielding H. Garrison in "Garrison's History of Neurology" (still available in a new edition revised by Dr. Lawrence McHenry),⁴ and by the ne west addition to the f ield in the mon umental "Handbook of Clinical Neurology," edited by Dr. Finger and his colleagues.⁵ These latter sources allow one to follow developments in the f ield more easily than in the book by Dr. Bhattacharyya, who has chosen to pr esent his characters in alphabetical or der (albeit with content divided into "the Beginning" and "the Modern Age").

In terms of content and form, the more than 400 pages in "Eminent Neurolo gists" are a pleasur e to r ead. Dr. Bhattacharyya's choice of characters is, on the w hole, quite judicious. His writing style is light but appropriate, and he narrates personal anecdotes with gusto, bringing those "giants" down to real earth. He accompanies each article with a picture (with a few exceptions), and for this he must be commended because that alone m ust have represented an enormous amount of work.

There is another nice f eature: Dr . Bhattachar yya makes a point of providing the reader with the names of people who have written extensive reviews of the life and work of the neuroscientists he mentions, such as Michael Aminoff's work on Charles-Édouar d Brown-Séquard. He tends to be historically accurate (with a few exceptions).

As can be e xpected (and f orgiven), the length and depth of the articles vary a great deal. Less expected and often hard to swallow is, in too many instances, a poorly proofread text with misspellings not only of foreign words, but also of the very name of the persons he writes about. For instance James Papez's name is correct in the title and at the beginning of the article, but further down the page, the famous circuits become "Papaz Cir cuits" and f ive lines do wn "P aper Cir cuits." Quick, Dr. Bhattacharyya, bring us soon a new edition with these errors corrected, and your book will be an even greater delight to read.

References

1. Haymaker W. The Founders of Neurology. Springfield, IL: Charles C Thomas Publisher Ltd.; 1953.

2. Haymaker W, Schiller F. The Founders of Neurology. 2nd ed. Springfield, IL: Charles C Thomas Publisher Ltd.; 1970.

3. Finger, S. Minds Behind the Brain: A Histor y of the Pioneers and their Discoveries. New York, NY: Oxford University Press; 2000.

4. McHenry L.C., ed. Garrison's History of Neurology. Rev ed. Springfield, IL: Charles C Thomas Publisher Ltd., 1969.

5. Finger S., et al., eds. History of Neurology. Amsterdam, the Netherlands: Elsevier; 2010. Handbook of Clinical Neurology, vol. 95.

Continued from previous page

ALS, or FTD-ALS patients ar e not accounted for. In spor adic FTD, which is more common than familial FTD, then the rate of C9ORF72 mutations appears to be between 2% and 5%," Dr. Schulz said

Effect of Other FTD/ALS Mutations

The new C9ORF72 expansion joins two other mutations found in patients with FTD and/or ALS, namely, those affecting the genes for microtubulin-associated protein tau (MAPT) and progranulin (GRN). In a commentary on the studies featured in Br ain, Dr. John Hodges of Neuroscience Research Australia and the University of New South Wales in Sydney, Australia, noted that the r esults of the London-based g roup (Br ain 2012;135:736-50) pro vide some insight into how likely it is that a patient would have a C9ORF72 mutation and whether this likelihood could be predicted based upon family history and clinical features.

The researchers found that the prevalences of the thr ee m utations w ere roughly equal in their sample. They also found - based on their Goldman scoring method for quantifying family history that 88% of patients with a scor e of 1 (representing an autosomal dominant

family history of FTD or ALS) had a mutation in one of those three genes.

However, the Mayo Clinic samples suggest that the C9ORF72 m utation is the most common FTD mutation, present in one-third of people with a family history.

Links Between FTD and ALS

The C9ORF72 m utation may also provide some insight on the link s between FTD and ALS. In all cohorts, the prevalence of C9ORF72 was highest in those

with FTD/ALS at 20%-40%, and a pproached 50% among FTD/ALS cases with a positive family history. Dr. Br ad Dickerson, director of the

frontotemporal dementia unit and laboratory of neu-

roimaging at Massachusetts Gener al Hospital in Boston, Mass ., USA, said that linking FTD and ALS through this gene was especially important because it would likely lead to research that sheds light on w hat causes cells in dif ferent parts of the brain to be vulner able in both of these diseases.

This once again underscores the value that studying one neurodegenerative disease can have for other neurodegenerative disease," he said. "In the case of this gene, advances in understanding its role in FTD will have direct implications for understanding its role in ALS, and vice versa."

Dr. Mar sel Mesulam, dir ector of the cognitive neurology and Alzheimer's disease center at Northwestern University in Chicago, USA, said that "exactly how the hopes raised by the C9ORF72 finding will be realized is currently unclear, since we do not yet fully understand the function

It's still a puzzle why the mutation causes ALS, FTD, and/or primary progressive aphasia in different patients. **DR. MESULAM**

of C9ORF72." He added that the discovery also generates ne w puzzles . "Why does the same type of mutation cause ALS in some patients, behavioral FTD in others, and PP A

[primary pro gres-

sive aphasia] in still others?'

Behavioral Variant FTD Most Common

The behavioral variant of FTD was the most common clinical phenotype associated with the C9ORF72 expansion, and was often accompanied by features of ALS as the disease progressed.

Some studies sho wed that patients with the C9ORF72 m utation also pr esented with progressive nonfluent aphasia. Major psy chiatric symptoms also were very common, but more details are needed, Dr. Hodges wrote.

Who Should Undergo Screening?

Given that some patients had the C9ORF72 m utation e ven without a strong family history, "the most important immediate clinical implication is that we will likel y be gin screening patients for this mutation once a standard laboratory test f or this gene becomes available," Dr. Dickerson said.

In a commentar y, Rosa Rademakers, Ph.D., of the Mayo Clinic in Jacksonville, Fla., USA, argued that the use of a clinical screening algorithm may not work because detailed information about family histor y is often una vailable. At the moment, caution is ad vised on testing because "our pr esent under standing of the disease penetrance and range of clinical phenotypes associated with this mutation is poor and the smallest repeat size needed for pathogenicity is unknown," Dr. Rademakers wrote.

The sources interviewed for this article did not ha ve any relevant financial disclosures. Dr. R ademakers disclosed that she has a patent pending on the discovery of the hexanucleotide repeat expansion in the C9ORF72 gene.



Announcing the launch of MULTIPLE SCLEROSIS AND RELATED DISORDERS

Register for a FREE one-year subscription!*

Chief Editors

Dr. Brenda Banwell, Prof. Gavin Giovannoni, Prof. Christopher H. Hawkes, Prof. Fred D. Lublin

Multiple Sclerosis and Related Disorders – New title published by Elsevier

This quarterly published journal will start its official publication in January 2012.

Register for a **FREE one-year subscription** for this journal today!*

Submit your registration form online at: http://bit.ly/ndCw9W

Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on Multiple Sclerosis and associated disease of the nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues.

With your annual subscription, you will receive...

- Four print issues of MSARD covering the very latest high quality original research, review articles and commentaries in the field
- Searchable online access to the full text content resource of all current and past issues
- Clinically relevant original articles, abstracts, and more

Register for FREE One-year subscription today! Scan the code with your smart phone

Need a code reader for you phone? www.getneoreader.com *Limited number of free subscriptions available.



ISSN: 2211-0348 Catalogue 2012: Volume 1, 4 issues Advance issue, October 2011 www.MSARD-journal.com

